The aim of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and immunogenicity of ES102 in combination with Toripalimab in subjects with advanced non-small cell lung cancer (NSCLC).
Having sufficient understanding of this study and being willing to sign the informed consent form (ICF).
Males or females, age 18-75 years at the time of signing the informed consent form.
Histologically or cytologically confirmed, unresectable locally advanced and metastatic non-small cell lung cancer not suitable for radical concurrent chemoradiotherapy.
Without known EGFR mutation/ALK fusion/ROS1 fusion gene.
Any prior therapy targeting OX40.
Receipt of any other investigational drug or device intervention within 28 days prior to the first dose of the study drug.
Receipt of anticancer Chinese herbal therapy within 14 days prior to the first dose of the study drug.
Receipt of radiotherapy within 14 days prior to the first dose of the study drug.